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Abstract 
Background: Retinol-binding protein 4 (RBP4) is an adipokine identified as a marker of 
insulin resistance in mice and humans. Protein tyrosine phosphatase 1B (PTP1B) expression 
levels, as well as other genes involved in the endoplasmic-reticulum (ER) stress response, are 
increased in adipose tissue of obese, high-fat diet fed mice. In this study, we investigated if 
serum- and/or adipose-tissue RBP4 protein levels, and expression levels of PTP1B and other 
ER stress-response genes, are altered in obese and obese/diabetic men resident in North East 
of Scotland.  
Methods: We studied three groups of male volunteers: 1) normal/overweight (body mass 
index (BMI) <30), 2) obese (BMI>30) and 3) obese/diabetic group (BMI>30) controlling 
their diabetes either by diet or anti-diabetic drug, metformin. We analysed their serum- and 
adipose-tissue RBP4 protein levels, as well as adipose tissue mRNA expression of PTP1B, 
BIP (binding immunoglobulinprotein), ATF4 (activated transcription factor 4) and GRP94 
(glucose-regulated protein 94), alongside other markers of adiposity (% body fat, leptin, 
cholesterol, triglycerides) and insulin resistance (oral glucose tolerance tests (OGTT), insulin, 
HOMA-IR, C-reactive protein (CRP), adiponectin).  
Results: We found that obese Scottish subjects had significantly higher serum-RBP4 protein 
levels in comparison to the normal/overweight subjects (p<0.01).  Serum-RBP4 levels were 
normalized in obese/diabetic subjects treated with diet or metformin (p<0.05). Adipose-tissue 
RBP4 protein levels were comparable between all three groups of subjects and so were 
serum- and adipose-transthyretin (TTR) levels. Adipose-tissue PTP1B mRNA levels were 
increased in obese subjects in comparison to normal/overweight subjects (p<0.05), however 
diet and/or metformin treatment did not reverse this effect. Adipose-tissue BIP, ATF4 and 
GRP94 expression levels were unchanged in obese and obese/diabetic subjects.  
Conclusions: Human obesity results in an increase in serum, but not adipose-tissue, RBP4 
protein levels and these are normalized in obese/diabetic subjects, which exhibit 
improvements in insulin sensitivity through diet or metformin treatment. However, whilst 
adipose-tissue PTP1B mRNA levels do increase in obese Scottish subjects, these remain high 
in obese/diabetics on diet or metformin treatment.  
 
Abbreviations: retinol-binding protein 4 (RBP4), transthyretin (TTR), oral glucose tolerance 
test (OGTT), c-reactive protein (CRP), homeostasis-model-assessment of insulin resistance 
(HOMA-IR), body mass index (BMI), protein tyrosine phosphatase 1B (PTP1B), BIP 
(binding immunoglobulinprotein), ATF4 (activated transcription factor 4) and GRP94 
(glucose-regulated protein 94) 
 
Introduction 
Obesity is a major risk factor for a number of metabolic diseases such as type 2 
diabetes, cardiovascular disease, cancer, Alzheimer’s disease and others. Recent studies 
clearly demonstrate that adipose tissue acts as an endocrine and paracrine organ, by secreting 
various proteins (adipokines) 1. These bioactive molecules, including leptin, adiponectin, 
visfatin, omentin, tumor necrosis factor-α (TNF-α), resistin, retinol-binding protein 4 (RBP4) 
and many others influence metabolic processes such as food intake, glucose and lipid 
metabolism, inflammation and insulin resistance (reviewed in 2). Adipose tissue is an 
important inflammatory source in obesity and type 2 diabetes, due to the cytokines produced 
by the adipose tissue itself as well as macrophages that have infiltrated the adipose tissue 
during the progression of obesity 3.  
RBP4 is an adipokine recently discovered to be elevated in insulin-resistant states and 
obesity in mice 4 and humans 3,5. RBP4 is a transport protein for retinol (vitamin A) and is 
normally bound to transthyretin (TTR) in circulation. In many studies, the level of serum 
RBP4 elevation correlates highly with the degree of insulin resistance in both mice and 
humans, and serum RBP4 levels are suggested to be highly predictive of metabolic syndrome 
risk in a large population-based study 6. However, not all studies agree with these findings 
and find that either serum RBP4 levels are unaltered in insulin resistance/diabetes, or that 
RBP4 mRNA levels in human abdominal subcutaneous tissue levels are even down-regulated 
in obesity (for commentary see 7).   
Protein-tyrosine phosphatase 1B (PTP1B) is a ubiquitously expressed non-receptor 
tyrosine phosphatase and a key negative regulator of leptin and insulin signalling 1. High-fat 
diet feeding in mice has been shown to increase PTP1B levels in a number of tissues such as 
the brain, muscle, liver and adipose tissue 1,8-10, and global PTP1B−/− mice exhibit reduced 
adiposity and improvements in insulin sensitivity 11,12. However, this improvement in insulin 
sensitivity is tissue-specific as adipose-specific PTP1B−/− mice exhibit an increase in leptin 
production and mild glucose intolerance 1. Low-grade inflammation, such as that caused by 
obesity and prolonged high-fat diet feeding, has been shown to lead an induction of the 
endoplasmic-reticulum stress 13-15 and result in an increase in PTP1B protein and mRNA 
expression levels 10,16. Increase in ER stress response genes, such as BIP (binding 
immunoglobulinprotein), ATF4 (activated transcription factor 4) and GRP94 (glucose-
regulated protein 94) in mice is associated with obesity and insulin resistance. 
In this study we aimed to investigate if serum and adipose tissue RBP4 protein levels 
are altered in human obesity and type 2 diabetes in a cohort of men resident in North East of 
Scotland and if this can be manipulated by either diet or metformin treatment in 
obese/diabetic subjects. As the method of measuring RBP4 levels has been suggested to 
account for some of the discrepancies in findings between different studies and quantitative 
Western blotting for protein RBP4, using full-length RBP4 antibody, has been suggested as a 
‘gold standard’ for RBP4 level determination 17, we used this method to assess both serum 
and adipose tissue RBP4 protein levels in normal/overweight, obese and obese/diabetic 
subjects and correlated these to other markers of obesity and insulin resistance. In addition, 
whilst there is evidence to support that obesity and high-fat diet feeding leads to induction of 
ER stress response and induction of ER stress-response genes in adipose tissue in mice 13, to 
our knowledge, there is not much data available if this is also the case in humans. We 
therefore analyzed PTP1B expression levels and levels of BIP, ATF4 and GRP94 in adipose 
tissue of normal/overweight subjects and compared it to obese and obese/diabetic subjects 
resident in North East of Scotland.  
Methods 
Volunteers and protocols 
Male, non-smoking subjects were included if they were not on any special-diet and had a 
normal medical examination excluding their diabetic status, where appropriate. Only those 
diabetic volunteers who were controlling their diabetes by diet or metformin (500 mg 4 times 
a day) were accepted. These inclusion criteria were also checked with the participant’s 
primary-care physician. All patients provided informed written-consent before inclusion in 
the study, approved by North of Scotland Research Ethics Committee (NOSREC).  
The study comprised of three groups (see Table 1): normal/overweight volunteers with a BMI 
<30 (n=21), obese volunteers with a BMI >30 (n=9) and obese/diabetic volunteers with a 
BMI >30 (n=14) controlling their diabetes by diet or metformin. All blood samples were 
taken overnight-fasted (10-12 hours). Each subject’s height, weight, waist and hip were 
measured using standard protocols 18. Percentage body fat was determined using air-
displacement whole-body plethysmography (BodPod® Body Composition System, CT, 
USA). 
Fat biopsies 
A subcutaneous, abdominal region, adipose-tissue biopsy was taken after an overnight-fast 
(10-12 hours). The biopsy was performed in the periumbilical triangle with a 14G needle, 
after intradermal anaesthesia with 2% lignocaine. Adipose-tissue was drawn by successive 
suctions into a 50ml syringe. We routinely obtain 0.5-1 gram of adipose-tissue. Tissue was 
immediately frozen in liquid nitrogen. Samples were subsequently processed for RNA and 
protein extraction.  
Oral-Glucose Tolerance Testing (OGTT) 
Volunteers were fasted overnight (10-hours) to receive the OGTT. Blood samples were 
drawn at 0- and 120-minutes after consuming 75g of glucose. Plasma glucose levels (and 
triacylglycerol) were measured using an automated clinical analyzer (Kone Oyj, Espoo, 
Finland). Plasma insulin was measured using an enzyme-linked immunosorbent assay 
(Mercodia, Sweden). The inter- and intra-assay coefficients of variation (CVs) for insulin 
using this assay were 2.6%–3.6% and 2.8%–3.4%, respectively. Homeostasis-model-
assessment of insulin resistance (HOMA-IR) was calculated using fasting glucose and insulin 
values. Total cholesterol, LDL- and HDL-cholesterol were analysed using commercial kits 
(Microgenics Gmbh, UK).  
Plasma ELISAs  
Plasma leptin and CRP were detected, in duplicate, using commercial kits according to the 
manufacturer's instructions (R&D Systems, UK). For leptin the minimum level of detection 
was less than 7.8pg/ml and the intra- and inter-assay CVs were 3.2 and 4.2%, respectively. 
For CRP the minimum level of detection 0.005ng/ml and the intra- and inter-assay CVs were 
8.7% and 8.7%, respectively.  
Biochemical analyses 
Adipose-tissue lysates were prepared by extraction in RIPA buffer, as described previously 
1,19
. 10µg of human adipose-tissue lysates were used for analysis. Serum RBP4 levels were 
measured by adding 1µl of patients’ serum directly into 29 µl of 1% SDS loading-buffer and 
boiling for 10 minutes 20. Proteins were resolved by SDS-PAGE (10% gels in MES buffer), 
transferred to nitrocellulose membranes and immunoblots performed using polyclonal 
antibodies against anti-human RBP4 and TTR, following manufacturer’s instructions.  
Proteins were visualized using enhanced-chemiluminescence (ECL), and quantified using a 
high-sensitivity imaging system (Fusion imaging system and Bio1D software, Vilber 
Lourmat) 1,10,19,21. 
mRNA expression analysis 
Total RNA was isolated from adipose tissue using TRI Reagent® (Ambion,Warrington, 
U.K.) according to the manufacturer’s protocol. First-strand cDNA was synthesized from 1 
µg of total RNA employing the BiorscriptTM Preamplification System (Bioline, London, 
U.K.) and an oligo(dT)12–18 primer as the reverse primer. Then, target genes were amplified 
by real-time PCR using GoTaqTM qPCR Master Mix (Promega, Southampton, U.K.) in 
Roche LightCycler® 480 System (Roche Diagnostics, Burgess Hill, U.K.). Relative gene 
expression was calculated using the comparative Ct (2−∆∆Ct) method as described previously 
10
. 
 
Statistical analyses 
The statistical package GraphPad Prism 5 was used for analysis. Results are reported as 
mean ± SD. One way ANOVA was performed for analysis of more than 2 variables followed 
by post hoc test for detection of significance. Simple linear correlation (Pearson's correlation) 
was used for quantitative data. Spearman correlation coefficient was used for qualitative data 
to estimate the association of RBP4 levels and BMI, leptin, insulin, adiponectin, CRP, 
cholesterol, triglycerides, HOMA-IR, SLPI, waist/hip ratio, lean weight, fat mass and % fat 
mass. P value is significant if p≤0.05.  
Results 
Three groups of male subjects were recruited into the study (see Table 1). The study 
comprised of a group of normal/overweight subjects with a BMI<30 (n=21), an obese group 
with a BMI>30 (n=9) and a similar obese group, with a BMI>30, who in addition were 
diagnosed with diabetes (n=14) controlled by diet or metformin. Whilst there were no 
significant differences in age or height of the volunteers, they had significantly different waist 
circumference (1-way ANOVA; p<0.001), BMI (p<0.001), % body fat (p<0.001), waist/hip 
ratio (p<0.001) and leptin (p<0.01) (Table 1). In addition, markers of insulin resistance 
between the three groups were significantly different, namely oral glucose tolerance test 
(OGTT) at 0 and 2 hours (p<0.001), fasting plasma glucose and insulin (p<0.001), HOMA-IR 
(p<0.001) and serum triglycerides (p<0.05).  
As the method of measuring RBP4 levels has been suggested to account for some of the 
discrepancies in findings between different studies and Western blotting for protein RBP4, 
using full-length RBP4 antibody, has been suggested as a ‘gold standard’ for RBP4 level 
determination 17, we used this method to assess both serum- and adipose-tissue RBP4 protein 
levels in normal/overweight, obese and obese/diabetic subjects and correlated these to other 
markers of adiposity and insulin resistance. By using anti-human RBP4 and TTR antibodies, 
we found that obese subjects had significantly higher serum RBP4 protein levels in 
comparison to the normal/overweight subjects (1-way ANOVA; p<0.01; treatment effect 
p=0.005, F=6.046) (Fig. 1A, B). Furthermore, in obese/diabetic subjects treated with either 
diet or metformin, serum RBP4 protein levels were completely normalized (1-way ANOVA; 
p<0.05) (normal/overweight 1.34x106 ±0.26x106 vs obese 1.64x106 ±0.18x106 vs 
ovese/diabetic 1.40x106±0.17x106), whilst serum TTR protein levels remained unaltered (Fig. 
1A, C). Interestingly, whilst serum RBP4 levels were up-regulated in human obesity and 
normalized by improving whole body insulin sensitivity in obese subjects, the adipose-tissue 
RBP4 protein levels were comparable between all three groups of subjects (Fig. 2A, B), as 
were the serum and adipose tissue TTR levels (Fig. 1A, C; Fig. 2A, C).  
To assess if serum and/or adipose RBP4 protein levels correlated with any of the 
adiposity or insulin sensitivity markers, we performed additional correlation analysis using 
Speaman correlation coefficient (R) as done previously 5. Whilst body mass index (BMI) 
correlated significantly, as expected, to serum leptin (R=0.89; p<0.0001), insulin (R=0.72; 
p<0.0001), adiponectin (R=-0.48; p<0.01), CRP (R=0.46; p<0.01), triglycerides (R=0.36; 
p<0.05) and HOMA-IR (R=0.72; p<0.0001), we found no correlation between serum and/or 
adipose RBP4 protein levels and any of the above mentioned adiposity- and insulin-
sensitivity markers (Table 2).  
To assess if obesity led to an increase in ER stress-response genes in the adipose 
tissue of our subjects, and if this could be reversed by insulin sensitization, we analyzed 
adipose tissue gene expression of PTP1B, BIP, ATF4 and GRP94. In agreement with mouse 
studies, adipose tissue PTP1B gene expression levels were increased in obese subjects in 
comparison to the normal/overweight group (Fig. 3A) 1. However, this was not reversed with 
insulin sensitization in obese/diabetic subjects treated with diet or metformin, suggesting that 
in humans, like in mice, adipose tissue PTP1B does not regulate insulin sensitivity 1. Gene 
expression levels of other ER stress response genes were not regulated by obesity or insulin 
sensitivity (Fig. 3B-D). 
 
Discussion 
RBP4 is an adipokine proposed to be a marker of human insulin resistance, type 2 
diabetes 5 and gestational diabetes. RBP4 levels have been found to be normalized by certain 
anti-diabetic drug treatments such as rosiglitazone or pioglitazone 7and lowering RBP4 levels 
has been suggested as a potential anti-diabetic therapy. However, many studies have not been 
able to show this association between human obesity and insulin resistance and found no 
correlation between BMI and serum and/or adipose tissue mRNA RBP4 levels 22.  
In our volunteer study, we demonstrate that serum- but not adipose-tissue RBP4 
protein levels are elevated in human obesity. We also show that this can be completely 
reversed in obese/diabetic subjects treated with diet or metformin, in agreement with studies 
from other patient cohorts 5. Thus, improved insulin sensitivity in this small cohort study may 
be at least partly due to the lowering effects of diet or metformin on serum, but not adipose 
tissue, RBP4 levels. However, in agreement with other studies which found no correlation 
between the actual body mass index 22 and serum RBP4 levels, we also show that serum and 
subcutaneous adipose-tissue RBP4 protein levels do not correlate with BMI, nor do they 
correlate to any other known investigated adiposity- and insulin-sensitivity markers. This 
suggests that there may be other factor(s) responsible for the observed rise in serum RBP4 
protein levels during the progression of human obesity. Some studies, however, have found 
an association between serum RBP4 levels and visceral fat (VF) 23,24and it is possible that 
serum RBP4 levels would correlate directly to those; since we did not have accurate data on 
VF for each volunteer, normally obtained by MRI, we cannot exclude the possibility that 
these would show a correlation. 
We also demonstrate that in human subcutaneous adipose tissue, PTP1B expression 
levels are regulated by obesity, in agreement with the mouse studies which demonstrate that 
adipose tissue PTP1B levels are up-regulated upon high-fat diet feeding 1. In agreement with 
the mouse studies, furthermore, we also observe that an increase in adipose tissue PTP1B 
levels in human obesity cannot be reversed by improvements in insulin sensitivity in 
obese/diabetic subjects treated with diet or metformin.  
On the other hand, the levels of the other ER stress response genes remain unaltered 
in the adipose tissue of the three study groups, suggesting that perhaps ER stress response 
pathway may not play a major role in this tissue in human obesity. We should however be 
cautious at interpreting these data due to a relatively low sample size that we had available 
for this specific study and perhaps a larger study size is required to quantitatively examine the 
role of ER stress response pathway in human obesity.  
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 Figure Legends 
Figure 1. Serum RBP4 protein levels in normal/overweight, obese and obese/diabetic 
subjects treated with diet or metformin.  
A) Serum  RBP4 and TTR protein levels. 1 microliter of serum was denatured in SDS 
loading buffer and subjected to SDS-PAGE analysis per individual.  Quantification of serum 
B) RBP4 and C) TTR protein levels using Bio1D quantitative software.  
Figure 2. Adipose-tissue RBP4 protein levels in normal/overweight, obese and 
obese/diabetic subjects treated with diet or metformin.  
A) Adipose tissue RBP4 and TTR protein levels. 10 micrograms of adipose tissue lysate was 
denatured in SDS loading buffer and subjected to SDS-PAGE analysis per individual.  
Quantification of adipose tissue B) RBP4 and C) TTR protein levels using Bio1D 
quantitative software.  
Figure 3. Adipose tissue  relative mRNA levels of PTP1B, ATF4, GRP94 and BiP.  
Graphs A to D show relative mRNA levels of the indicated genes in adipose tissue, measured 
by quantitative real-time PCR and normalized against HPRT mRNA. n=9 for 
Normal/Overweight group; n=7 for Obese group and n=8 for Obese/Diabetic/Treated group. 
Data are represented as mean +/- SEM and analyzed using 1-way ANOVA with post-hoc 
analysis. 
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  Normal/Overweig
ht 
Obese Obese/ 
Diabetic 
P value 
(ANOVA) 
n 21 9 14  
Age 46.1 (9.2) 54.8 (13.8) 52.8 (13.2) 0.2 
Waist circumference (cm) 89.6 (5.7) 113  (6.5) 120.2 (11.5) <0.001 
Body Mass Index (Kg/m2) 25.5 (2.10) 34.3 (5.02) 36.7 (6.3) <0.001 
Height (m) 1.76 (0.64) 1.78 (0.08) 1.74 (0.66) 0.351 
Body Weight (Kg) 79.2 (7.6) 109 (13.8) 111 (18.5) <0.001 
Body Weight/Height 
Ratio 
0.51 (0.04) 0.64 (0.05) 0.69 (0.07) <0.001 
Percentage Body Fat 22.8 (6.8) 38.3 (6.1) 38.2 (7.0) <0.001 
Waist/Hip Ratio 0.88 (0.05) 0.96 (0.07) 1.05 (0.14) <0.001 
Plasma Cholesterol 
(mmol/l) 
4.73 (1.32) 5.24 (1.06) 4.38 (0.49) 0.17 
Plasma HDL Cholesterol 
(mmol/l) 
1.28 (0.33) 1.15 (0.34) 1.19 (0.27) 0.54 
Plasma LDL Cholesterol 
(mmol/l) 
3.08 (1.11) 3.38 (0.80) 2.54 (0.42) 0.082 
Triglycerides (pmol/l) 1.09 (0.52) 1.42 (0.53) 1.80 (1.08) 0.04 
OGTT Plasma Glucose 0 
hour (mmol/l) 
5.42 (0.74) 5.88 (0.68) 8.92 (2.82) <0.001 
OGTT Plasma Glucose 2 
hour (mmol/l) 
5.22 (2.13) 4.75 (1.3) 13.8 (3.80) <0.001 
Fasting Plasma Insulin 
(mU/I) 
4.74 (2.77) 9.81 (4.03) 16.3 (10.6) <0.001 
Fasting Plasma Leptin 
(ng/ml) 
4.08 (1.88) 15.60 (12.34) 19.44 (8.84) 0.006 
C-reactive Peptide (µg/ml) 1.22 (1.82) 2.39 (1.50) 2.78 (2.29) 0.127 
HOMA-IR 1.19 (0.91) 2.66 (1.25) 6.39 (4.24) <0.001 
HOMA beta cell 52.6 (26.7) 80.9 (33.2) 84.6 (60.3) 0.032 
QUICKI 1.12 (0.22) 1.44 (0.21) 1.66 (0.24) <0.001 
 
Table 1. Baseline characteristics of the lean/overweight, obese and diabetic study volunteers. 
Lean/overweight volunteers have a waist circumference <40 inches (101.6 cm). Data are 
mean (standard deviation) for all parameters. P values shown on the right are One-Way 
ANOVA analysis of variance. 
 Clinical Features: Normal/Overweight 
N=12 
Obese  
N=9 
Obese/Diabetic  
N=11 
Variables: r p r p r p 
BMI -0.01 0.487 -0.45 0.114 -0.17 0.307 
Leptin -0.43 0.107 -0.2 0.307 0.23 0.251 
Insulin -0.03 0.457 0.23 0.276 -0.31 0.177 
Adiponectin -0.16 0.309 0.27 0.247 0.52 0.051* 
CRP -0.315 0.159 -0.53 0.074 -0.12 0.364 
Cholesterol 0.15 0.324 -0.07 0.44 0.43 0.09 
Triglycerides 0.21 0.252 0.12 0.388 -0.06 0.426 
HOMA-IR -0.06 0.431 0.37 0.168 -0.24 0.242 
SLPI -0.23 0.235 0.32 0.205 -0.32 0.170 
Waist/Hip -0.08 0.406 0.30 0.218 0.03 0.462 
Lean Weight -0.17 0.301 -0.02 0.491 -0.47 0.071 
Fat mass -0.07 0.414 0.07 0.44 0.07 0.416 
% fat -0.01 0.483 -0.19 0.307 0.19 0.290 
 
Table 2. Correlations between plasma RBP4 and BMI, leptin, insulin, adiponectin, CRP, 
cholesterol, triglycerides, HOMA-IR, SLPI, waist/hip ratio, lean weight, fat mass and % fat 
mass. P value is significant if p≤0.05.  
 
 
 
 
 
 
 
